Latest MS research news

Latest MS research news | 29 October 2012

Protein-protein interaction analysis highlights additional loci of interest for MS

This study looked at protein-protein interaction analysis of gene products coded in loci recently reported to be MS associated at the genome-wide significance level and in loci suggestive of MS association.

From MSIF

Latest MS research news | 22 October 2012

Low degree of cortical pathology is associated with benign course of MS

In this study from Italy, they present the results from the 6-year extension of the previous 1-year prospective longitudinal study on the evolution of cortical pathology in a group of MS patients with relatively mild disease compared with a group of relapsing-remitting MS patients.

From MSIF

Latest MS research news | 22 October 2012

Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired MS patients

This interesting study from Germany carried out a multicentre, double-blind, randomised, placebo-controlled study, on the safety and efficacy of rivastigmine in cognitively impaired MS patients.

From MSIF

Latest MS research news | 22 October 2012

Cerebrospinal fluid biomarkers of B-amyloid metabolism in MS

This study looked at amyloid precursor protein (APP) degradation products in the CSF of MS patients at different stages of disease, in addition to the effects of disease modifying therapy.

From MSIF

Latest MS research news | 21 October 2012

Interferon beta for secondary progressive multiple sclerosis: a systematic review

This systematic review of interferon treatment in secondary progressive MS (SPMS) includes five randomised placebo controlled trials of IFN╬▓ in SPMS patients and found that although relapse rates were reduced in patients receiving treatment vs placebo, that disability progression was not.

From MSIF

Latest MS research news | 15 October 2012

Imaging resting state brain function in MS

This review article from Italy looks at different clinical stages in MS patients using resting state functional MRI (fMRI), which they used to investigate intrinsic brain activity across the whole brain and to measure the degree of functional correlation between different cortical regions.

From MSIF

Latest MS research news | 15 October 2012

Characterisation of anti-natalizumab antibodies in MS patients

This study from Sweden looked at the characterisation of anti-natalizumab antibodies in natalizumab-treated patients over a period of five years, as well as the persistence of the antibodies.

From MSIF

Latest MS research news | 15 October 2012

Multicontrast MR Imaging at 7T in MS: Highest Lesion Detection in Cortical Gray Matter with 3D-FLAIR

The researchers in this study looked prospectively at 37 MS patients, who underwent multicontrast 7T MR imaging including 2D-T2WI, 3D-T1WI, 3D-FLAIR and GM-specific 3D-DIR.

From MSIF

Latest MS research news | 08 October 2012

Severe relapses under fingolimod treatment prescribed after natalizumab

This research group from Italy looked at the rate of relapse following a change of treatment to fingolimod from natalizumab in 3 patients with relapsing-remitting MS.

From MSIF

Latest MS research news | 08 October 2012

Increase in MS activity after assisted reproduction technology

In this article from Argentina, the researchers looked at the changes in disease activity in patients with relapsing-remitting MS having assisted reproduction technology (ART) infertility treatment.

From MSIF
 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial